Vincent Hennemand is currently CEO of Covant Therapeutics, developing first-and best-in-class covalent therapeutics for the most significant drug targets. Prior to Covant, he was the COO at Intergalactic Therapeutics and previously Senior Vice President of Strategy, Corporate & Business Development at Akili Interactive Labs. Before that, he was a Principal in Sanofi’s corporate R&D venture group (“Sunrise”) where he was responsible for developing and managing new investment opportunities including Myokardia, Voyager Therapeutics, WarpDrive Bio, and Portal Instruments.